HDL Therapeutics To Go Public in Merger With Swiftmerge Acquisition Corp.; $480M Business Combination To Accelerate The Commercialization Of An Innovative Fda-approved Cardiovascular Disease Treatment
$480 million Business Combination to Accelerate the Commercialization of an Innovative FDA-Approved Cardiovascular Disease Treatment
HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held
